E. H. van Roekel

E. H. van Roekel is a researcher at the German Cancer Research Center (DKFZ) within the Division of Cancer Epidemiology and Department of Molecular Epidemiology. Their work focuses on molecular epidemiology of colorectal cancer, with specialization in metabolomics and nutritional factors influencing cancer outcomes.

Dr. van Roekel's research spans multiple critical areas in cancer epidemiology including tryptophan-kynurenine pathway metabolites, one-carbon metabolism, and B-vitamin biomarkers in relation to colorectal cancer progression and patient survival. They investigate how circadian rhythms affect cancer-related fatigue and quality of life in survivors, while also examining metabolic signatures associated with obesity and cancer risk. Their methodological expertise includes plasma metabolomic profiling and careful handling of biospecimens for research purposes, as evidenced by publications on pre-analytical factors in metabolomic studies.

Analysis of Dr. van Roekel's publication record reveals consistent involvement in large-scale international consortia including ColoCare and FOCUS, enabling robust epidemiological studies with substantial patient cohorts. Their research demonstrates a clear trajectory from basic metabolomic discovery to clinical applications, with increasing focus on how molecular findings translate to patient quality of life and survivorship outcomes. The collaborative nature of their work spans multiple European institutions and involves close partnerships with clinical oncologists, epidemiologists, and basic scientists.

Dr. van Roekel actively contributes to DKFZ's mission of advancing cancer research through participation in multi-center studies requiring careful standardization of protocols. While specific grant information isn't detailed in the available publications, their involvement in major research initiatives suggests successful funding from prominent cancer research organizations. Their work bridges laboratory findings with clinical applications, contributing to the development of potential biomarkers for cancer staging, recurrence prediction, and personalized treatment approaches.